Enliven Therapeutics Stock Price on July 30, 2024
| ELVN Stock | 24.38 1.03 4.05% |
Below is the normalized historical share price chart for Enliven Therapeutics extending back to March 12, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Enliven Therapeutics stands at 24.38, as last reported on the 30th of November, with the highest price reaching 25.63 and the lowest price hitting 24.30 during the day.
If you're considering investing in Enliven Stock, it is important to understand the factors that can impact its price. As of now, Enliven Stock is very steady. Enliven Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0665, which denotes the company had a 0.0665% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Enliven Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Enliven Therapeutics' Downside Deviation of 2.35, mean deviation of 2.01, and Coefficient Of Variation of 1670.35 to check if the risk estimate we provide is consistent with the expected return of 0.19%.
At this time, Enliven Therapeutics' Stock Based Compensation is very stable compared to the past year. As of the 30th of November 2024, Sale Purchase Of Stock is likely to grow to 1,208, while Issuance Of Capital Stock is likely to drop about 505.3 K. . At this time, Enliven Therapeutics' Price Book Value Ratio is very stable compared to the past year. As of the 30th of November 2024, Price Earnings To Growth Ratio is likely to grow to 0.11, while Price Earnings Ratio is likely to drop (7.22). Enliven Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 12th of March 2020 | 200 Day MA 22.2555 | 50 Day MA 26.7076 |
Enliven |
Sharpe Ratio = 0.0665
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ELVN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.82 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Enliven Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enliven Therapeutics by adding it to a well-diversified portfolio.
Price Book 4.3048 | Book Value 6 K | Enterprise Value 949.8 M | Enterprise Value Ebitda (6.28) | Shares Float 25.5 K |
Enliven Therapeutics Main Headline on 30th of July 2024
Acquisition by Collins Helen Louise of 20000 shares of Enliv... by Collins Helen Louise
Filed transaction by Enliven Therapeutics Officer Chief Medical Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Enliven Therapeutics Valuation on July 30, 2024
It is possible to determine the worth of Enliven Therapeutics on a given historical date. On July 30, 2024 Enliven was worth 26.75 at the beginning of the trading date compared to the closed value of 26.13. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Enliven Therapeutics stock. Still, in general, we apply an absolute valuation method to find Enliven Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Enliven Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Enliven Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 27.45 | 27.67 | 26.29 | 26.56 | 244,936 | |
07/30/2024 | 26.75 | 26.79 | 25.35 | 26.13 | 131,582 |
| 26.40 | 27.67 | 26.12 | 26.38 | 836,918 |
| Backtest Enliven Therapeutics | | | Enliven Therapeutics History | | | Enliven Therapeutics Valuation | Previous | Next |
Enliven Therapeutics Trading Date Momentum on July 30, 2024
| On July 31 2024 Enliven Therapeutics was traded for 26.38 at the closing time. The top price for the day was 27.67 and the lowest listed price was 26.12 . The trading volume for the day was 836.9 K. The trading history from July 31, 2024 was a factor to the next trading day price boost. The overall trading delta against the next closing price was 0.96% . The overall trading delta against the current closing price is 17.15% . |
Enliven Therapeutics Fundamentals Correlations and Trends
By evaluating Enliven Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Enliven financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Enliven Therapeutics Stock history
Enliven Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Enliven is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Enliven Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Enliven Therapeutics stock prices may prove useful in developing a viable investing in Enliven Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 35.5 M | 37.3 M | |
| Net Loss | -22.3 M | -23.4 M |
Enliven Therapeutics Quarterly Net Working Capital |
|
Enliven Therapeutics Stock Technical Analysis
Enliven Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Enliven Therapeutics Period Price Range
Low | November 30, 2024
| High |
0.00 | 0.00 |
Enliven Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Enliven Therapeutics November 30, 2024 Market Strength
Market strength indicators help investors to evaluate how Enliven Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Enliven Therapeutics shares will generate the highest return on investment. By undertsting and applying Enliven Therapeutics stock market strength indicators, traders can identify Enliven Therapeutics entry and exit signals to maximize returns
Enliven Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Enliven Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Enliven Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Enliven to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.053 | |||
| Jensen Alpha | 0.0314 | |||
| Total Risk Alpha | (0.31) | |||
| Sortino Ratio | 0.0119 | |||
| Treynor Ratio | 0.1599 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.